Skip to content

Harrow HROW EV / EBITDA

EV / EBITDA at other companies

AbbVie logo
AbbVieABBV
19.8×
Bausch + Lomb logo
Bausch + LombBLCO
16.1×-3.1×
Viatris logo
ViatrisVTRS
9.6×
Bausch Health Companies logo
Bausch Health CompaniesBHC
12×+3.9×
PBH
Prestige Consumer HealthcarePBH
11.1×-3.1×
Organon logo
OrganonOGN
-1.0×

Other financials

Income statement

See full
Revenue$44.2M-7.6%
Gross profit$27.0M-16.3%
Operating income-$22.1M-96.6%
Net income-$27.6M-55.2%
EPS (diluted)-$0.74-48.0%

Balance sheet

See full
Cash & equivalents$94.6M+41.8%
Total debt$308.6M-32.9%
Total equity$28.7M-49.1%
Total assets$419.5M+15.2%

Cash flow

See full
Operating cash flow-$9.0M-146%
CapEx$194.0K+14.1%
Free cash flow-$9.2M-147%

Valuation

See full
Market cap$1.59B+38.4%
Enterprise value$1.81B+13.8%
P/S5.9×+0.5×

Profitability

See full
Gross margin74.1%-0.4pp
Operating margin7.3%+5.2pp
Net margin-19.8%+18.0pp
FCF margin5.7%+5.0pp

Returns & leverage

See full
Return on equity-50%+17.5pp
Debt / equity10.7×+2.6×
Current ratio2.5×+1.6×

Where this comes from

Calculated from Harrow’s reported figures.

Based on the most recent quarter.

The official record: Harrow’s 10-Q, filed May 11, 2026, on SEC EDGAR. View the filing →

Ask your AI about Harrow's ev / ebitda.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Harrow's EV / EBITDA?
Harrow (HROW) reported EV / EBITDA of 70.8× in Q1 2026.
How has Harrow's EV / EBITDA changed year-over-year?
Harrow's EV / EBITDA decreased by 66.2% year-over-year, from 209.6× to 70.8×.
What is the long-term trend for Harrow's EV / EBITDA?
Over 3 years (2022 to 2025), Harrow's EV / EBITDA has grown at a -3.1% compound annual growth rate (CAGR), from 67.7× to 61.7×.
What does EV / EBITDA mean?
Enterprise value (market cap plus total debt minus cash) at the quarter end divided by trailing-twelve-month EBITDA. A capital-structure-neutral valuation multiple.